1Mahadeo KM, Santizo R, Baker L, et al. Ambulatory high-dose metho- trexate administration among pediatric osteosarcoma patients in an ur- ban, underserved setting is feasible, safe, and cost effective[ J J. Pediatr Blood Cancer,2010,55 (7) : 1296-1299. 被引量：1
2Plaza-Plaza J C, Aguilera M, Canadas-Garre M, et al. Pharmacogenetie polymorphisms contributing to toxicity induced by methotrexatein the southern Spanish population with rheumatoid arthritis [ J~. OMICS, 2012,16( 11 ) :589-595. 被引量：1
3Ongaro A, de M at te iM, Della PortaMG, et al. Gene polym orphisms info late metabolizing enzymes in adu It acute lymphob last ic leukem ia:E ffects on m ethotrexate-related toxicity and sun, iv, l[ JJ. H aem a tologica,2009,94(10) : 1391-1398. 被引量：1
4刘新春等主编..实用抗肿瘤药物治疗学[M].北京:人民卫生出版社,2002:1125.
5Frosst P,Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease:a common mutation in methylenetetrahydro-folate re- ductase [ J ~. Nat Genet, 1995,10 ( 1 ) : 111-113. 被引量：1
9Carter S. The dilemma of sdjuvant chemotherapy for osteosarcoma [ J ]. Cancer Clin Trial, 1980,3 ( 1 ) : 29 - 36. 被引量：1
10Colom H, Farre R, Soy D, et al. Population pharmacokinetics of high - dose methotrexate after intravenous administration in pediatric patients with osteosarcoma [ J]. Ther Drug Monit ,2009,31 ( 1 ) : 76 - 85. 被引量：1
